Loading...
Home2019-04-30T07:45:40+00:00

Innovative scientific approaches have facilitated significant progress in drug development during recent decades, offering amazing new treatment options to patients across a range of chronic diseases. However, safety and tolerability of drug candidates and newly approved drugs often remain a key concern, leading to labelling restrictions, black box warnings, and withdrawal of otherwise promising innovative medicines.

Latest News

TransBioLine Press Release

April 23rd, 2019|Latest News|

Innovative Medicines Initiative Launches Translational Safety Biomarker Pipeline Project The University of Zurich coordinates a worldwide [...]

TransBioLine Kick off Meeting

April 23rd, 2019|Events|

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy [...]

Clinical study

April 28th, 2019|Clinical Studies|

Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has been the industry's standard dummy [...]

TransBioLine promises a decisive advance in biomarker discovery, development, validation, regulatory qualification and application, and bring about a fundamental change in the way drug safety is monitored in clinical trials, and toxicities are diagnosed and managed in clinical practice.

Mission
This website uses cookies and third party services. Ok